BRD-glucan exhibits potent immunochemotherapeutic activity in vitro and in vivo

  • Authors:
    • Seong-Hoon Moon
    • Jin-Chul Heo
    • Robert L. Fine
    • Hwan-Mook Kim
    • Sung-Uk Kim
    • Byung-Dae Yoon
    • Sang-Han Lee
  • View Affiliations

  • Published online on: February 1, 2005     https://doi.org/10.3892/ijo.26.2.395
  • Pages: 395-404
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We carried out in vitro and in vivo assays to investigate the immunomodulatory and immunochemotherapeutic action mechanism of BRD-glucan, a high molecular weight (≈3,500 kDa) polysaccharide isolated from Aureobasidium sp, and assessed the efficacy of BRD-glucan/adriamycin co-treatment of animal cancer models. RT-PCR and suspension hemolytic, plaque forming, wounding, invasion and cell proliferation assays were utilized to investigate the in vitro immunochemotherapeutic effects of BRD-glucan. In vivo, the effects of BRD-glucan and BRD-glucan/adriamycin co-treatment were tested in a B16 melanoma initiation model and in C57BL/6 mice. In vitro, BRD-glucan did not affect the cellular wounding response or invasion activity; treatment with BRD-glucan led to increase proliferation of B cells, natural killer cells and macrophages, but not T cells. In addition, we found that the BRD-glucan activation of B cells and macrophages was dependent on Toll-like receptor2 (TLR2) and TLR4, which play important roles in innate and adaptive immunity. In vivo, BRD-glucan/adriamycin co-treatment effectively reduced the number and size of metastatic colonies. Based on the results of our in vitro and in vivo toxicity, safety and immunochemotherapy assays, we propose that BRD-glucan is a promising immunochemotherapeutic anti-tumor agent.

Related Articles

Journal Cover

February 2005
Volume 26 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Moon S, Heo J, Fine RL, Kim H, Kim S, Yoon B and Lee S: BRD-glucan exhibits potent immunochemotherapeutic activity in vitro and in vivo. Int J Oncol 26: 395-404, 2005
APA
Moon, S., Heo, J., Fine, R.L., Kim, H., Kim, S., Yoon, B., & Lee, S. (2005). BRD-glucan exhibits potent immunochemotherapeutic activity in vitro and in vivo. International Journal of Oncology, 26, 395-404. https://doi.org/10.3892/ijo.26.2.395
MLA
Moon, S., Heo, J., Fine, R. L., Kim, H., Kim, S., Yoon, B., Lee, S."BRD-glucan exhibits potent immunochemotherapeutic activity in vitro and in vivo". International Journal of Oncology 26.2 (2005): 395-404.
Chicago
Moon, S., Heo, J., Fine, R. L., Kim, H., Kim, S., Yoon, B., Lee, S."BRD-glucan exhibits potent immunochemotherapeutic activity in vitro and in vivo". International Journal of Oncology 26, no. 2 (2005): 395-404. https://doi.org/10.3892/ijo.26.2.395